Tiziana Life Sciences Ltd (TLSA) Options

Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab

What is wrong with TLSA after all the positive news lately? Why is the pps going down instead of up?

.80 TLSA ..03:30 PM EST, 01/23/2025 (MT Newswires) -- Tiziana Life Sciences (TLSA) said Thursday that preclinical studies of foralumab, a nasal anti-CD3 monoclonal antibody, in traumatic spinal cord injury showed notable improvements in motor functions.

☝️😁☝️🌎🚀

tlsa......................https://stockcharts.com/h-sc/ui?s=tlsa
&p=W&b=5&g=0&id=p86431144783

now at my entry

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with nasal foralumab. We believe these findings contribute substantially to our understanding of the immune mechanisms underlying the effects of nasal foralumab.

The study identified gene expression changes which were detected beginning three months after intranasal dosing of foralumab in our ongoing ISPPEA (or expanded access program). Key findings include modulation of:

FoxP3 T regulatory cells (Tregs)
CD4+ and CD8+ central memory T cells
CD14+ and CD14- monocytes
Naïve B cells
These pathways are known to be associated with antigen presentation, interferon responses, and other regulatory immune mechanisms.

In this study, single-cell RNA sequencing (scRNAseq) of peripheral blood samples taken before and at three and six months after drug administration has revealed relevant gene expression changes associated with nasal foralumab, which has been associated with a reduction in microglial brain inflammation, as measured by advanced microglial PET scans in these same patients.

“We are excited to announce this breakthrough in understanding how nasal foralumab induces immune modulation in Secondary Progressive MS patients,” said Dr. Tanuja Chitnis, M.D., Principal Investigator and Professor of Neurology at Harvard Medical School and senior neurologist at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System. “These findings highlight the potential of nasal foralumab in modulating critical immune pathways and offer new insights into its clinical effects. This discovery represents a pivotal step toward personalized treatment strategies for MS. We look forward to submitting these data to a peer reviewed journal.”

“The observed clinical stabilization and microglial PET findings are supported by these new biomarker discoveries, providing compelling evidence of nasal foralumab's biological effects,” said Dr. Howard Weiner, Chairman of Tiziana’s Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham healthcare system. “The identification of these biomarkers not only strengthens our understanding of the treatment’s mechanism but also establishes a framework for monitoring its efficacy in future trials and may establish a framework for monitoring a patient’s response to foralumab treatment.”

“This data, and its implications, underscores our commitment to advancing innovative therapies for neurodegenerative diseases,” commented Ivor Elrifi, CEO of Tiziana Life Sciences. “Foralumab, the first fully human anti-CD3 monoclonal antibody, is in a Phase 2 trial as a groundbreaking immunomodulatory therapy with applications in autoimmune and neurodegenerative diseases. These findings further confirm its potential and set the stage for broader clinical exploration.”

The FDA defines a biomarker as a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Molecular, histologic, radiographic, or physiologic characteristics are types of biomarkers. A biomarker is not an assessment of how an individual feels, functions, or survives.

About Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program with either an improvement or stability of disease seen within 6 months in all patients. The FDA has recently allowed an additional 20 patients to be enrolled in this EA program. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).

Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal

Someone is on the bid.... Late MS - only one out there

TLSA for progressive MS
smart and genuine CEO in good "company"
https://en.wikipedia.org/wiki/Howard_L._Weiner
https://finance.yahoo.com/news/tiziana-life-sciences-announces-live-110000183.html

TLSA under $2

TLSA under $2

TLSA.........................https://stockcharts.com/h-sc/ui?s=TLSA&p=W&b=5&g=0&id=p86431144783

TLSA...FULL OUT WEEKLY BREAK OUT!!!!

TLSA...NEXT BIO BEAST READY TO FLY, NOT A BETTER CHART OUT THERE

TLSA 10Q expected JULY8

TLSA 10Q expected July 1

TLSA 10Q expected Monday 6/24

TLSA new 52 week low

Alot of room here

The 9s + breakout coming

Green day!! Volumes been consistent getting into a groove here

https://newsdirect.com/news/tiziana-life-sciences-reports-six-month-pet-scan-results-for-ms-patients-545441035

Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment https://www.globenewswire.com/news-release/2023/10/18/2762186/0/en/Tiziana-Life-Sciences-Announces-Allowance-By-FDA-For-At-Home-Dosing-Of-Intranasal-Foralumab-For-Multiple-Sclerosis-Treatment.html

$TLSA

News

https://marketwirenews.com/news-releases/tiziana-life-sciences-announces-allowance-by-fda-for-8463755861297756.html

https://marketwirenews.com/articles/tiziana-life-sciences-plc-nasdaq-tlsa-short-squeeze--mwn-news-4013.html

Easy imo

Gm all

coffee and DD

good setup to pop from here

under the radar $TLSA

$1 yup

Next stop 1$ +

im in

Same here

$TLSA keeping an eye here

Big week ahead!!

Nice volume today!!!

I am worried about the same thing because i received multiple emails last night about this stock which an indication there might be doing an offering

Let's get it

Thinking so ! Once we break 9s we might fly

room to move up some?

Hmm

Most definitely!!?

overdue?

Interested here

When .9s fall were gonna start moving fast

what does this show?

Looking up here $$ volumes been getting juicy

What we have here

Not going to zero but there will be a capital raise